Intracellular iron chelation modulates the macrophage iron phenotype with consequences on tumor progression

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Mertens, Christina ^a   Akam, Eman Abureida ^b   Rehwald, Claudia ^a   Brüne, Bernhard ^a   Tomat, Elisa ^b   Jung, Michaela ^a  

^a GOETHE UNIVERSITY   (Germany)

^b University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; IRON CHELATING AGENT; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IRON CHELATION; IRON TRANSPORT; MACROPHAGE; MCF 7 CELL LINE; METASTASIS; POLARIZATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ATOMIC ABSORPTION SPECTROMETRY; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HOMEOSTASIS; MCF-7 CELL LINE; METABOLISM; PHARMACOLOGY; PHENOTYPE;

CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IRON; IRON CHELATING AGENTS; MACROPHAGES; MCF-7 CELLS; PHENOTYPE; SPECTROPHOTOMETRY, ATOMIC; TUMOR MICROENVIRONMENT;

EID: 84994386042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0166164     Document Type: Article

References (56)

1. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-69. doi: 10.1038/nri2448 PMID: 19029990
2. Labonte AC, Tosello-Trampont AC, Hahn YS. The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells. 2014; 37(4):275-85. doi: 10.14348/molcells.2014.2374 PMID: 24625576
3. Jung M, Sola A, Hughes J, Kluth DC, Vinuesa E, Vinas JL, et al. Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int. 2012; 81(10):969-82. doi: 10. 1038/ki.2011.446 PMID: 22278021
4. Sola A, Weigert A, Jung M, Vinuesa E, Brecht K, Weis N, et al. Sphingosine-1-phosphate signalling induces the production of Lcn-2 by macrophages to promote kidney regeneration. J Pathol. 2011; 225 (4):597-608. doi: 10.1002/path.2982 PMID: 22025214
5. Jung M, Brune B, Hotter G, Sola A. Macrophage-derived Lipocalin-2 contributes to ischemic resistance mechanisms by protecting from renal injury. Sci Rep. 2016; 6:21950. doi: 10.1038/srep21950 PMID: 26911537
6. Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, De Pizzol M, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010; 40(3):824-35. doi: 10.1002/eji.200939889 PMID: 20039303
7. Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011; 32(6):241-7. doi: 10.1016/j.it.2011.03.007 PMID: 21514223
8. Nairz M, Schroll A, Sonnweber T, Weiss G. The struggle for iron-a metal at the host-pathogen interface. Cell Microbiol. 2010; 12(12):1691-702. doi: 10.1111/j.1462-5822.2010.01529.x PMID: 20964797
9. Weiss G. Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol. 2005; 18(2):183-201. doi: 10.1016/j.beha.2004.09.001 PMID: 15737884
10. Nairz M, Schroll A, Haschka D, Dichtl S, Sonnweber T, Theurl I, et al. Lipocalin-2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. Eur J Immunol. 2015; 45(11):3073-86. doi: 10.1002/eji.201545569 PMID: 26332507
11. Recalcati S, Locati M, Cairo G. Systemic and cellular consequences of macrophage control of iron metabolism. Semin Immunol. 2012; 24(6):393-8. doi: 10.1016/j.smim.2013.01.001 PMID: 23375134
12. Zhang Y, Cheng S, Zhang M, Zhen L, Pang D, Zhang Q, et al. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013; 8(9):e76147. doi: 10.1371/journal.pone.0076147 PMID: 24098773
13. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009; 1790 (7):702-17. doi: 10.1016/j.bbagen.2008.04.003 PMID: 18485918
14. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology. 2002; 16(9 Suppl 10):17-24. PMID: 12380951
15. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010; 119(2):283-93. doi: 10.1007/s10549-009-0345-x PMID: 19238537
16. Rossiello R, Carriero MV, Giordano GG. Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol. 1984; 37(1):51-5. PMID: 6323544
17. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, et al. IRP2 regulates breast tumor growth. Cancer Res. 2014; 74(2):497-507. doi: 10.1158/0008-5472.CAN-13-1224 PMID: 24285726
18. Jiang XP, Elliott RL, Head JF. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res. 2010; 30(3):759-65. PMID: 20392994
19. Pogribny IP, Tryndyak VP, Pogribna M, Shpyleva S, Surratt G, Gamboa da Costa G, et al. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents. Int J Oncol. 2013; 42(5):1822-32. doi: 10.3892/ijo.2013.1855 PMID: 23483119
20. Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene. 2012; 31(2):213-25. doi: 10.1038/onc.2011.228 PMID: 21666721
21. Jian J, Yang Q, Shao Y, Axelrod D, Smith J, Singh B, et al. A link between premenopausal iron deficiency and breast cancer malignancy. BMC Cancer. 2013; 13:307. doi: 10.1186/1471-2407-13-307 PMID: 23800380
22. Freitas I, Boncompagni E, Vaccarone R, Fenoglio C, Barni S, Baronzio GF. Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement. Anticancer Res. 2007; 27(5A):3059-65. PMID: 17970045
23. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010; 2(43):43ra56. doi: 10.1126/ scisignal.3001127 PMID: 20686179
24. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57(4):547-83. doi: 10.1124/pr.57.4.2 PMID: 16382108
25. Hatcher HC, Singh RN, Torti FM, Torti SV. Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem. 2009; 1(9):1643-70. doi: 10.4155/fmc.09.121 PMID: 21425984
26. Blatt J, Boegel F, Hedlund BE, Arena VC, Shadduck RK. Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. Leuk Res. 1991; 15(5):391-4. PMID: 2046391
27. Akam EA, Chang TM, Astashkin AV, Tomat E. Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. Metallomics. 2014; 6(10):1905-12. doi: 10.1039/c4mt00153b PMID: 25100578
28. Chang TM, Tomat E. Disulfide/thiol switches in thiosemicarbazone ligands for redox-directed iron chelation. Dalton Trans. 2013; 42(22):7846-9. doi: 10.1039/c3dt50824b PMID: 23591852
29. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992; 45(5):416-9. PMID: 1350788
30. Niewiadomska H, Jeziorski A, Olborski B. The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma. J Exp Clin Cancer Res. 1998; 17(4):503-10. PMID: 10089075
31. Bories G, Colin S, Vanhoutte J, Derudas B, Copin C, Fanchon M, et al. Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res. 2013; 113(11):1196-205. doi: 10. 1161/CIRCRESAHA.113.301656 PMID: 24036496
32. Recalcati S, Minotti G, Cairo G. Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal. 2010; 13(10):1593-616. doi: 10.1089/ars.2009.2983 PMID: 20214491
33. Baby SM, Roy A, Mokashi AM, Lahiri S. Effects of hypoxia and intracellular iron chelation on hypoxiainducible factor-1alpha and -1beta in the rat carotid body and glomus cells. Histochem Cell Biol. 2003; 120(5):343-52. doi: 10.1007/s00418-003-0588-2 PMID: 14600837
34. Siddiq A, Aminova LR, Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res. 2007; 32 (4-5):931-46. doi: 10.1007/s11064-006-9268-7 PMID: 17342411
35. Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog. 2013; 18(5):435-48. PMID: 23879588
36. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013; 13(5):342-55. doi: 10.1038/nrc3495 PMID: 23594855
37. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011; 71(21):6728-37. doi: 10.1158/0008-5472.CAN-11-1870 PMID: 21875943
38. Gaetano C, Massimo L, Alberto M. Control of iron homeostasis as a key component of macrophage polarization. Haematologica. 2010; 95(11):1801-3. doi: 10.3324/haematol.2010.030239 PMID: 21037324
39. Jezequel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guerin-Charbonnel C, et al. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study. Int J Cancer. 2012; 131(2):426-37. doi: 10.1002/ijc.26397 PMID: 21898387
40. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle. 2007; 6 (16):1982-94. doi: 10.4161/cc.6.16.4603 PMID: 17721086
41. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, Richardson DR. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem. 2012; 287(21):17016-28. doi: 10.1074/jbc.M112. 350470 PMID: 22453918
42. Jung M, Mertens C, Brune B. Macrophage iron homeostasis and polarization in the context of cancer. Immunobiology. 2015; 220(2):295-304. doi: 10.1016/j.imbio.2014.09.011 PMID: 25260218
43. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66(2):605-12. doi: 10.1158/0008-5472.CAN-05-4005 PMID: 16423985
44. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006; 42(6):717-27. doi: 10.1016/j.ejca.2006.01.003 PMID: 16520032
45. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006; 25(3):315-22. doi: 10.1007/s10555-006-9001-7 PMID: 16967326
46. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliafico E, Bosurgi L, et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica. 2010; 95 (11):1814-22. doi: 10.3324/haematol.2010.023879 PMID: 20511666
47. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003; 101(10):4148-54. doi: 10.1182/blood-2002-08-2459 PMID: 12522003
48. Nairz M, Schleicher U, Schroll A, Sonnweber T, Theurl I, Ludwiczek S, et al. Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection. J Exp Med. 2013; 210(5):855-73. doi: 10.1084/jem.20121946 PMID: 23630227
49. Nairz M, Fritsche G, Brunner P, Talasz H, Hantke K, Weiss G. Interferon-gamma limits the availability of iron for intramacrophage Salmonella typhimurium. Eur J Immunol. 2008; 38(7):1923-36. doi: 10. 1002/eji.200738056 PMID: 18581323
50. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008; 84(3):623-30. doi: 10.1189/jlb.1107762 PMID: 18467655
51. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007; 9(4):212. doi: 10.1186/bcr1746 PMID: 17705880
52. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012; 109(8):2796-801. doi: 10.1073/pnas.1104303108 PMID: 21825174
53. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat. 2013; 137(3):733-44. doi: 10.1007/s10549-012-2405-x PMID: 23306463
54. Dorner MH, Silverstone A, Nishiya K, de Sostoa A, Munn G, de Sousa M. Ferritin synthesis by human T lymphocytes. Science. 1980; 209(4460):1019-21. PMID: 6967622
55. MarquesO. PortoG. RemaA. FariaF. Cruz PaulaA. Gomez-LazaroM.et al.Local iron homeostasis in the breast ductal carcinoma microenvironmentBMC Cancer2016161187
56. Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun Rev. 2012; 11(12):883-9. doi: 10.1016/j.autrev. 2012.03.003 PMID: 22449938